The set domain containing 2 (SETD2) histone methyltransferase, located at 3p2, specifically trimethylates lysine 36 of histone H3 (H3K36me3). H3K36me3 is an active mark involved in transcriptional elongation and RNA processing, and a key regulator of DNA repair. In fact, SETD2 is the only methyltransferase that "writes" the H3K36me3 Thus, SETD2 links chromatin and cytoskeleton homeostasis through its methyltransferase activity. These studies have important implications on the role of SETD2 mutations in promoting genomic instability and tumor progression.
Introduction
Defects in chromatin modifying proteins have come to define distinct subsets of both rare and common cancers. Defects in SWI/SNF chromatin remodeling complexes, for example, occur in approximately 20% of all cancers (1) . Loss-of-function of one of these complex members, SMARCB1 (SNF5/INI1/BAF47), defines rare, but very aggressive, malignant rhabdoid tumors (MRT) (2, 3) and renal medullary carcinomas (RMC) (4) (5) (6) . In the kidney, in addition to MRTs and RMCs, renal cell carcinoma (RCC) is also characterized by defects in chromatin modifiers. Over 95% of clear cell RCCs exhibit 3p loss, resulting in co-deletion of a cluster of chromatin modifier genes on the short arm of chromosome 3: the histone methyltransferase SETD2, the SWI/SNF component PBRM1, and the histone deubiquitinase BAP1 (7, 8) . Subsequent "second-hit" mutations in these genes result in loss-of-function, and contribute to progression of RCC, and in the case of SETD2 and BAP1, are associated with aggressive tumors and the lethal phenotype (7, 9) .
SETD2 in Cancer
SETD2 is a histone methyltransferase responsible for the H3K36me3 methyl mark on histones (10) . In addition to rare cancers such as clear cell RCC, glioblastoma multiforme and pancreatic cancers, which are significantly associated with inactivating mutations of SETD2, a significant frequency of SETD2 alterations is observed in several more common tumors (Figure 1 ), including melanoma (11), bladder and lung cancer (cbioportal), which also exhibit alterations in other chromatin modifiers such as the SWI/SNF complex SMARCA4 ATP-ase subunit (12) .
New Functions for SETD2 in Cancer
Park et al. have now discovered a new function for SETD2 and revealed a previously unknown linkage between the epigenome and the cytoskeleton (13) . They found that in addition to histones, SETD2 also methylates α-tubulin , and that methylation is a new post-translational modification of microtubules. They showed that SETD2 directly binds α-tubulin, and can methylate α-tubulin in an in vitro methyltransferase assay. They were able to generate an antibody to the site of methylation on microtubules, lysine 40, and using this α-TubK40me3 antibody, showed that methylation occurred on dynamic microtubules during mitosis and cytokinesis. Importantly, they also showed that this microtubule methyl mark was required for genomic stability, as loss of SETD2 caused chromosome segregation errors, micronuclei and polyploidy. Thus, loss of genomic stability is a new mechanism by which defects in SETD2 and possibly other chromatin modifiers can drive oncogenesis.
In support of the importance of SETD2 function at the cytoskeleton, Park et al. (16) , and the BAF57 member of the SWI/SNF complex confers a pro-metastatic migratory phenotype on prostate cancer cells (17) . SET1A, a member of the COMPASS complex histone methyltransferase (18) is upregulated breast cancer tumors and cell lines, and ablation of SETD1A leads to a decrease in migration and invasion in vitro and to a decrease in metastasis in nude mice (19) . While these authors linked this phenotype to altered epigenetic regulation of expression of genes such as matrix metalloproteinases, it would now be important to explore whether these, and other chromatin modifiers, could also be acting at the cytoskeleton. 
